Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin O ? FDA says no

This article was originally published in The Tan Sheet

Executive Summary

R-Garden, marketer of dietary supplement Vitamin O, has been issued a warning letter regarding numerous violations of the FD&C Act, FDA says. Advertising claims made in mailings, customer testimonials and product descriptions found on the firm's website and in literature classify the supplement as a drug, and therefore would require an NDA, the agency states in the Feb. 8 letter. Questionable claims include testimonials that the oxygen-infused salt water, which can be topically applied or internally ingested, "took a skin cancer off my nose," "help[ed] control angina" and "stops gum infection and pain." R-Garden lacks sufficient scientific evidence to back its claims, the agency says, adding the product does not bear adequate dosing instructions, listed ingredients or recommended daily intakes...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel